

Reference number(s)
2085-A

## SPECIALTY GUIDELINE MANAGEMENT

### TRELSTAR (triptorelin pamoate)

#### POLICY

##### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

- A. FDA-Approved Indication  
Palliative treatment of advanced prostate cancer
- B. Compendial Use  
Prostate Cancer  
Preservation of ovarian function

All other indications are considered experimental/investigational and not medically necessary.

##### II. CRITERIA FOR INITIAL APPROVAL

- A. **Prostate cancer**  
Authorization of 12 months may be granted for treatment of prostate cancer.
- B. **Preservation of ovarian function**  
Authorization of 3 months may be granted for preservation of ovarian function when the member is premenopausal and undergoing chemotherapy.

##### III. CONTINUATION OF THERAPY

- A. **Prostate cancer**  
Authorization of 12 months may be granted for continued treatment in members requesting reauthorization who are experiencing clinical benefit to therapy (e.g., serum testosterone less than 50 ng/dL) and who have not experienced an unacceptable toxicity.
- B. **Preservation of ovarian function**  
Authorization of 3 months may be granted for continued treatment for preservation of ovarian function in members requesting reauthorization who are premenopausal and are still undergoing chemotherapy.

##### IV. REFERENCES

1. Trelstar [package insert]. Madison, NJ: Allergan Inc.; May 2020.
2. The NCCN Drugs & Biologics Compendium® © 2021 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed February 3, 2021.

Reference number(s)
2085-A

3. Clowse MEB, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. *J Womens Health (Larchmt)*. 2009 Mar; 18(3): 311–319. doi:10.1089/jwh.2008.0857.
4. Munhoz RR, et al. The role of LHRH agonists in ovarian function preservation in premenopausal women undergoing chemotherapy for early stage breast cancer: A systematic review and meta-analysis. Poster presented at: ASCO; May 29-June 2, 2015; Chicago, IL.
5. Oktay K, Harvey BE, et al: Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. *Journal of Clinical Oncology* 36:1994-2003, 2018.
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/breast.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf). Accessed February 12, 2021.